A Safety and Efficacy Study Evaluating CTX110 in Subjects With Relapsed or Refractory B-Cell Malignancies (CARBON)

Phase 1/2 Terminated 93 enrolled CRISPR Therapeutics AG

NaSequentialOpen-labelTreatment

Summary

This is an open-label, multicenter, Phase 1/2 study evaluating the safety and efficacy of CTX110 in subjects with relapsed or refractory B-cell malignancies.

Timeline

Start: 2019-07-22
Primary completion: 2024-10-04
Completion: 2024-10-04

Outcome

Met primary endpoint

Stopped: “Patients to be followed up in the CRSP-ONC-LTF study”

release “On October 21, 2020 , CRISPR Therapeutics announced positive top-line results from its ongoing Phase 1 CARBON trial evaluating the safety and efficacy of CTX110” crisprtx.com ↗

Publications

McGuirk JP, Ghobadi A, Bachier CR, Shaughnessy PJ, Awan FT, Maakaron JE, Bishop MR, Ho PJ, Tam CS, Dickinson MJ, Darrah JM, Waller EK, Murthy HS, Ross A, Williams LM, Pan C, Stevens WN, Serwer L, Nguyen T, Terrett J, Kalaitzidis D, Ma A, Xu H, Benton MD, Weaver A, Cohen SB, Maziarz RT, Cheah CY. Safety and efficacy of allogeneic CD19-directed CAR-T therapy CTX110 in relapsed/refractory B-cell non-Hodgkin lymphoma. Blood Adv. 2026 May 5:bloodadvances.2026020123. doi: 10.1182/bloodadvances.2026020123. Online ahead of print.

Drugs

Evaluation	Drug	Modality	Dose	Route
Subject	CTX110	Cell therapy	—	Intravenous